Please wait while we prepare your medical assistant...
Read
Biomarker explainers, longevity research and product updates — in one feed.
Reference catalogs →
Gepotidacin, zoliflodacin, zosurabalpin and sulbactam-durlobactam are four drugs for three different bacteria at three different levels of evidence. What each trial measured, in whom, and why the circulating "90.1% cure" figure has no trial behind it.
Tirzepatide has a sleep-apnea indication; semaglutide 1 mg has a kidney one; semaglutide 2.4 mg has an accelerated liver approval on a biopsy endpoint. Which drug, which dose, which population, which endpoint — and where the evidence stops.
Six one-time genetic treatments are licensed in the United States for sickle cell disease, beta-thalassemia, hemophilia and SMA. What the labels say about eligibility, how many years anyone has actually been followed, and what the boxed warnings record.
Rapamycin, metformin and TAME, senolytics, klotho. A plain look at the endpoints the human trials actually used — a scan, a marker, a questionnaire, a biopsy — and at what has not been shown in people.
An oral GLP-1 was approved in April 2026, and a much-discussed amylin combination missed its head-to-head endpoint. Here is what each trial measured, in whom and for how long — and which figures come from a paper rather than a company release.
Cell therapies built for blood cancers have put a few dozen people with refractory lupus, myositis and systemic sclerosis into drug-free remission — in case series and phase 1 trials. How many exactly, which remission standard, how long the follow-up — and why none of it is a treatment option yet.
A p-tau217 blood test has had regulatory clearance since May 2025, and two anti-amyloid antibodies are approved for early symptomatic disease. Here is what each one measured, in whom, over how long — and what none of it says.
VERVE-102 and CTX310 edit liver genes to lower LDL cholesterol after a single infusion. The 2026 papers report large drops in a few dozen selected patients — open-label, no placebo, and not one cardiovascular event counted.
Four investigational drugs lower lipoprotein(a) sharply in phase 2 trials. In September 2026 the first trial that counted heart attacks and strokes missed its endpoint. What was measured, on whom, and what the result does not settle.
Retatrutide, a once-weekly drug acting on three hormone receptors, now has published phase 3 trials in obesity and type 2 diabetes. Here is how much weight participants lost, in whom, with which side effects, and what the trials have not yet measured.
Anti-VEGF injections have preserved vision in large randomised trials of regular treatment. Newer drugs and an implant were shown to be no worse at longer intervals, each with its own safety profile; the latest phase 3 results are still company-reported.
A TSH below the range with normal T4 and T3 often returns to normal on repeat. When it persists, large cohorts link a TSH below 0.1 to atrial fibrillation and fractures, but the one randomised trial of treatment was small and inconclusive.
Articles in this section are educational and are not medical advice, a diagnosis, or a prescription. Consult a qualified professional before acting on anything you read here.